Suggestions
Kathryn Skelding
Associate Professor, Cancer Cell Biology Group Leader at University of Newcastle
Kathryn Skelding is an accomplished researcher specializing in cancer cell biology, with a focus on cell signaling and developing targeted therapies for a variety of cancers.
Having completed her Ph.D. in Microbiology and Immunology with a focus on cancer at the University of Newcastle, Kathryn has made significant contributions to the field.
Her work has led to the initiation of a Phase II clinical trial using CAVATAK virus as a treatment for melanoma, breast, and prostate cancer.
In her post-doctoral studies, she delved into signal transduction pathways and the regulation of CaMKII function in neuronal cells.
Since 2012, Kathryn has led her own research group at the University of Newcastle, aiming to unravel cell signaling in cancer and develop targeted therapies, especially focusing on leukemias, breast cancer, and prostate cancer.
Throughout her career, Kathryn Skelding has been recognized with numerous awards for her excellence in innovation, translational research, and academic achievements.
Her ultimate goal is to enhance patient outcomes and quality of life by translating her research findings into clinical applications.
